Abstract

BackgroundPeritoneal fibrosis is the major cause of ultrafiltration failure, and intraperitoneal administration of Low Molecular Weight Heparin (LMWH) was reported to protect peritoneal function. But the exact mechanism of its influence on peritoneal structure and function is still unknown.MethodsA fibrosis model of rat was established by intraperitoneal (IP) administration of PD fluid and Erythromycin Lactobionate. Fifty-two rats were randomly divided into 6 groups: (1) normal control group (CON, n = 6); (2) normal saline group (NS, n = 10); (3) high-glucose group (GLU, n = 10); (4) heparin group (HEP, n = 6); (5) low dose LMWH group (LLMWH, n = 10); (6) high dose LMWH group (HLMWH, n = 10). Two hour peritoneal equilibration test was performed after 28 days of intervention. The peritoneum, mesentery and omentum were harvested, and evaluated by Hematoxylin-Eosin and Masson Trichrome staining. The expressions of HIF-1α, VEGF and TGF-β1 in parietal peritoneum were detected by IHC and RT-PCR (Reverse Transcriptase Polymerase Chain Reaction).ResultsCompared with group CON and NS, ultrafiltration volume and D2/D0 glucose in group GLU decreased significantly, D/Purea (Dialysate-Plasma ratio of urea), D/Palb (Dialysate-Plasma ratio of albumin), peritoneal thickness, neoangiogenesis and inflammatory reaction increased significantly (all P<0.05). Administration of heparin and LMWH markedly alleviated these above pathological changes. The protein and mRNA levels of HIF-1α, VEGF and TGF-β1 increased significantly in group GLU, and decreased significantly after administration of LMWH in a dose-dependent manner.ConclusionsLMWH ameliorates peritoneal function and inhibits peritoneal fibrosis, possibly through suppression of HIF-1α, VEGF and TGF-β1.

Highlights

  • Continuous Ambulatory Peritoneal Dialysis (CAPD) is a standard therapy for patients with end-stage renal failure

  • Peritoneal fibrosis is the major cause of ultrafiltration failure and death for CAPD patients [4]

  • Our previous clinical trials had confirmed that Low Molecular Weight Heparin (LMWH) could protect peritoneal structure and function, and that HIF-1α was up-regulated in CAPD patients depending on the extent of peritoneal fibrosis

Read more

Summary

Introduction

Continuous Ambulatory Peritoneal Dialysis (CAPD) is a standard therapy for patients with end-stage renal failure. Long-term CAPD would induce chronic sterile inflammatory state, loss of mesothelial cells, submesothelial thickening, neoangiogenesis and peritoneal fibrosis, and cause functional deterioration of the peritoneal membrane, with increasing peritoneal permeability to small solutes and reduced ultrafiltration volume (UF) [1]. Peritoneal fibrosis is the major cause of ultrafiltration failure and death for CAPD patients [4]. Our previous clinical trials had confirmed that LMWH could protect peritoneal structure and function, and that HIF-1α was up-regulated in CAPD patients depending on the extent of peritoneal fibrosis. Peritoneal fibrosis is the major cause of ultrafiltration failure, and intraperitoneal administration of Low Molecular Weight Heparin (LMWH) was reported to protect peritoneal function. The exact mechanism of its influence on peritoneal structure and function is still unknown

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call